common side effects of oseni
upper respiratory tract infection
other side effects
bone fracture
headache
nasopharyngitis
pharyngitis
comprehensive list of adverse effects
needed effects
alogliptin
pioglitazone
unwanted side effects
medical attention
alogliptin
pioglitazone side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
common side effect
nasopharyngitis
pain
upper respiratory tract infection
alogliptin
trial
patients with type diabetes
recent acute coronary syndrome
more patients
n =-rrb- on alogliptin therapy
congestive heart failure
chf
placebo
n =-rrb-
pioglitazone
proactive trial
study in patients with type diabetes
history of macrovascular disease
pioglitazone mg
day
given placebo in addition
standard of care
edema
patients
pioglitazone
n =-rrb-
placebo
n =-rrb- patients
treatment-emergent adverse events
least hospitalized congestive heart failure event
patients
receiving pioglitazone
patients
receiving placebo
primary objective of the
year
proactive trial
effect of pioglitazone on mortality
macrovascular morbidity in high-risk patients
significant difference between pioglitazone
placebo/standard care
time
first occurrence
first event
all-cause mortality
nonfatal myocardial infarction
mi
including
silent mi
stroke
acute coronary syndrome
cardiac intervention
coronary artery bypass grafting
percutaneous intervention
major leg amputation above the ankle
bypass surgery
revascularization in the leg
total of patients
receiving pioglitazone
least event
patients
receiving placebo/standard care
pioglitazone
edema
pitting edema
fluid retention
combination therapy
pioglitazone monotherapy trials
edema
n =-rrb-
n =-rrb-
n =-rrb- of patients
receiving mg
mg
mg of pioglitazone
weeks
pioglitazone in combination with a sulfonylurea
weeks
edema
n =-rrb-
n =-rrb-
n =-rrb- of patients
receiving mg
mg
mg of pioglitazone
study in patients with nyha class
heart failure
percentage of patients
experiencing chf progression during the study
patients
receiving pioglitazone
n =-rrb-
glyburide
n =-rrb-
postmarketing reports of congestive heart failure
patients
pioglitazone
reports
patients
history of a known history of heart disease
concomitant insulin use
alogliptin
hypertension
congestive heart failure
chf
hospitalizationpioglitazone
chf hospitalization
postmarketing reports
chf
known heart disease
concomitant insulin
alogliptin-pioglitazone
hypoglycemia
alogliptin
hypoglycemia
pioglitazone
hypoglycemia
alogliptin
pancreatitis postmarketing reports
acute pancreatitis
acute pancreatitis
n =-rrb- of patients
alogliptin mg
n =-rrb- of patients
active comparator
placebo in alogliptin
clinical trials
trial
cv
outcomes trial in patients with type diabetes
high cv risk
acute pancreatitis
n =-rrb- of patients
alogliptin
n =-rrb- of patients
receiving placebo
pioglitazone
elevated alt frequency
decreased hemoglobin
hematocrit
alogliptin
alt elevations
times
upper limit of normal
uln
alogliptin
treated patients
receiving comparator
placebo during clinical trials
trial
trial in patients with type diabetes
high cardiovascular risk
alt
uln
patients
receiving alogliptin
placebo patients
pioglitazone
hepatotoxic effects
pioglitazone
clinical trials
postmarketing cases of fatal
nonfatal hepatic failure
alogliptin
postmarketing reports
hepatic enzyme elevations
fulminant hepatic failurepioglitazone
elevated serum alanine aminotransferase
alt
postmarketing reports
alogliptin
hypersensitivity reactions
postmarketing reports
anaphylaxis
angioedema
rash
urticaria
severe cutaneous adverse reactions
stevens-johnson syndrome
pioglitazone
frequency
weight gain
edemapostmarketing reports
weight
alogliptin-pioglitazone
pain alogliptin
pain frequency
arthralgiapioglitazone
myalgia
pain
elevation in serum creatine phosphokinase
cpk
alogliptin
october
december
cases of severe arthralgia
fda
adverse event reporting system database
case
use
more dipeptidyl peptidase
inhibitor
cases
substantial reduction in prior activity level
patients
disabling
disabling joint pain
cases
symptoms
month
starting therapy
cases symptoms
month after discontinuation
positive rechallenge
cases
cases
involving use of a different dpp
inhibitor
sitagliptin
greatest number of cases
n =-rrb-
saxagliptin
n =-rrb-
linagliptin
n =-rrb-
alogliptin
n =-rrb-
vildagliptin
n =-rrb-
alogliptin
headache pioglitazone
headache
pioglitazone
postmarketing reports
macular edema
pioglitazone
bladder cancer
us fda
released results
review of pioglitazone
bladder cancer
data
use of this drug
increase risk of bladder cancer
year
prospective cohort study in diabetic patients
manufacturer
n
users
n
users
diagnosed cases of bladder cancer
users
cases
users
adjusted hazard ratio
hr
pioglitazone use
increased risk
hr
confidence interval
modest trend towards higher risk
increasing duration
trend
interim
year
year
found weaker associations
studies
significant association between exposure
drug
bladder cancer
association between cumulative dose
cumulative duration of exposure
bladder cancer
drug
increase in the risk of urinary bladder tumors
insufficient data
drug
tumor promoter for urinary bladder tumors
alogliptin-pioglitazone
nasopharyngitis
upper respiratory tract infection alogliptin
influenza
nasopharyngitis
upper respiratory tract infection pioglitazone
upper
respiratory tract infection
sinusitis
nasopharyngitis
postmarketing reports of bullous pemphigoid
requiring hospitalization
dipeptidyl peptidase
inhibitors
case
systemic immunosuppressive treatment
discontinuation of dpp
inhibitor
dipeptidyl peptidase
inhibitors
postmarketing reports
bullous pemphigoid
side effects of oseni
fda
healthcare professional for medical advice
anxiety
blurred vision
chest pain
chills
cold sweats
confusion
cool, pale skin
decreased urine output
depression
dilated neck veins
dizziness
extreme fatigue
fast heartbeat
headache
increased hunger
irregular breathing
irregular heartbeat
nausea
nightmares
seizures
shakiness
slurred speech
swelling of the face
fingers
feet
lower legs
tightness in the chest
troubled breathing
unusual tiredness
weakness
weight gain
blistering
peeling
loosening of the skin
bloating
blood in the urine
constipation
cough
darkened urine
diarrhea
difficulty with swallowing
feeling of discomfort
fever
increased urge
hives
itching
rash
indigestion
inflammation of the joints
muscle pain
hive-like swelling on the face
eyelids
lips
tongue
throat
hands
legs
feet
sex organs
loss of appetite
muscle aches
pain in the
lower abdomen
stomach
painful urination
pains in the stomach
side
abdomen
radiating
back
puffiness
swelling of the eyelids
eyes
face
lips
tongue
red skin lesions
purple center
red, irritated eyes
sore throat
sores
ulcers
white spots in the mouth
lips
swollen lymph glands
vomiting
yellow eyes
skin
change in vision
general feeling of tiredness
weakness
light-colored stools
severe joint pain
stomach pain, continuing
back pain
body aches
pain
ear congestion
loss of voice
sneezing
runny nose